Clinical trials: Phosphorus Metabolism Disorders
Hyperphosphatemia
Bioequivalence Study of BAY77-1931 Granule
The study is conducted as a randomized, non-blinded, 2-way crossover study. Target population is 60 Japanese healthy male adult subjects selected by screening examination which will be conducted within 4 weeks before the first…
- Trial name
- NCT01053676
- Testing
- Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule, Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Bayer
X-linked Hypophosphatemia
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab…
- Trial name
- NCT03920072
- Testing
- Burosumab
- Where
- 10 sites in France, Ireland and 2 more
- Volunteers
- 35 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
X-Linked Hypophosphataemia
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
This study aims to provide Health-related Quality of Life (HRQoL) data from children and adolescents with growing skeletons in the United Kingdom (UK), including those treated with burosumab or alternative XLH treatment, as part…
- Trial name
- NCT04819490
- Where
- 6 sites in United Kingdom
- Volunteers
- 32 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chronic Kidney Disease
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704678)
- Testing
- SBR759, Sevelamer HCl
- Where
- 15 sites in Japan, Taiwan
- Volunteers
- 203 people
- Sponsor
- Novartis Pharmaceuticals
Hyperphosphatemia
BAY 77-1931 Long-term Extension From Phase II Study
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
- Trial name
- NCT00769496
- Testing
- BAY 77-1931
- Where
- 14 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Bayer
Hyperphosphatemia
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings
- Trial name
- NCT06186934
- Testing
- the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those…
- Trial name
- NCT04767581
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 165 people
- Sponsor
- Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
The objectives of the study are to: Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants Establish the safety profile of burosumab for the treatment of…
- Trial name
- NCT02163577
- Testing
- burosumab
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 52 people
- Sponsor
- Kyowa Kirin, Inc.
Hyperphosphatemia, Chronic Kidney Disease
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
The primary objective is to assess the effects of colestilan on the pharmacokinetic profile of candesartan cilexetil when administered at the same time as, 1 hour before, and 3 hours after the first daily dose of colestilan…
- Trial name
- NCT01976572
- Testing
- colestilan, candesartan
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, Renal Insufficiency
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.
- Conditions
- Chronic Kidney Disease, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT01742611
- Testing
- ASP1585
- Where
- 5 sites in Japan
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Primary Objective: To demonstrate efficacy of Renvela tablets in the reduction of serum phosphorus in hyperphosphatemia in participants with chronic kidney disease not on dialysis.
- Trial name
- RECOVER (NCT03001011)
- Testing
- Sevelamer Carbonate (GZ419831)
- Where
- 38 sites in China
- Volunteers
- 202 people
- Sponsor
- Sanofi
Hyperphosphataemia
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.
- Trial name
- NCT02151643
- Testing
- PT20
- Volunteers
- 153 people
- Sponsor
- Phosphate Therapeutics
Hyperphosphatemia
Long-term Effect of Lanthanum Carbonate on Bone
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an…
- Trial name
- NCT00557323
- Testing
- Lanthanum carbonate
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- Shire
Hyperphosphatemia
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat…
- Trial name
- NCT02675998
- Testing
- Tenapanor
- Where
- 32 sites in United States
- Volunteers
- 219 people
- Sponsor
- Ardelyx
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
Hyperphosphataemia, ESRD
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
The objective of this non-interventional study is to confirm that with standard OsvaRen® treatment it is possible to achieve in at least 60% of the patients the levels of phosphorus, total calcium, and iPTH seen in the CALMAG…
- Trial name
- Steering (NCT01424787)
- Where
- 24 sites in Denmark, Germany and 2 more
- Volunteers
- 324 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
Expanded Access to Burosumab
Individual patient expanded access requests may be considered for patients who have no other treatment options
- Trial name
- NCT03775187
- Testing
- Burosumab
- Sponsor
- Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
- Trial name
- NCT01571596
- Testing
- KRN23
- Where
- 6 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin Co., Ltd.
End Stage Renal Disease, Kidney Failure
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial.
- Conditions
- End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia
- Trial name
- NCT01554982
- Testing
- ferric citrate
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 168 people
- Sponsor
- Keryx Biopharmaceuticals